Sarepta Provides Details About its Duchenne Drug Launch and Eases Some Fears

Sarepta Therapeutics (SRPT) - Get Report  has provided some details about its drug to treat boys with Duchenne muscular dystrophy or DMD. The company says in the fourth quarter, it recorded sales of $5.4 million for the drug known as Exondys 51. That's better than the analyst consensus. TheStreet's Adam Feuerstein writes the reported sales in the December quarter look good, and "puts to rest the worst-case fear of insurance reimbursement denials and roadblocks preventing any DMD boys from receiving treatment." The drug was approved in mid-September.